PSNL Overview

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is11.17 USD with a low forecast of 10.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Personalis Inc revenue for the last quarter amounts to 15.47M USD, decreased -24.91

Personalis Inc. EPS for the last quarter amounts to -0.29 USD, increased 61.11

Personalis Inc (PSNL) has 260 emplpoyees as of June 21 2026.

Today PSNL has the market capitalization of 1.10B USD.